Global Trispecific Antibodies Clinical Trials & Market Outlook 2024

PUBLISHED: June 1, 2024

PAGES: 140 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

Global Trispecific Antibodies Clinical Trials & Market Outlook 2024 Report Highlights:

Trispecific Antibodies In Clinical Trials: > 50 Antibodies
Majority Of Antibodies Developed For Multiple Myeloma: 8 Antibodies
Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
Platforms Used For Pioneering Trispecific Antibody
China Dominating Trispecific Antibodies Clinical Trials: >20 Antibodies
Competitive Landscape: Insight On 18 Companies

The blueprint in the domain of immunotherapy has perceived futuristic with the advent of antibody founded therapy, like monospecific and bispecific antibodies, in the past decenniums. The investigation has picked up its gait after the FDA approval of the first monoclonal antibody, rituximab, for the management of patients suffering from non-Hodgkin's lymphoma. Albeit, the monospecific antibodies have demonstrated gigantic triumph, there comes a number of pitfalls, such as their ability to target only one type of antigens as well as increased therapy resistance, urges the need to develop more therapies that will target more than one antigen or foreign foe inside the person's body. In the recent years, trispecific antibody has emerged as a promising therapeutic target due to its plausibility in targeting 3 antigens at the same time, making it a game changer candidate for intervention in various ailments.

To date, no trispecific antibody have been launched in the market; however, it is probable that handful of trispecific antibodies will be approved in the imminent years. Founded on the accomplishment of monospecific antibodies, healthcare professionals have developed trispecific antibody, which can simultaneously bind to three different antigens at the same time, enhancing the precision and effectiveness of targeting tumor cells; representing a groundbreaking innovation in the field of cancer immunotherapy.

At present, more than 50 trispecific antibodies are lately in the preclinical together with clinical studies for the treatment of cancer, infectious diseases, and eye diseases. Nevertheless, researchers believed that the clinical conduit of trispecific antibody is proposed to perceive swift development in the years ahead and will likely expand into additional therapeutic areas like autoimmune diseases, and beyond. As progression in trispecific antibody understanding, mode of action in addition to protein engineering innovations upsurges; simultaneously, the unconventional design of trispecific constructs tailored to precise disease biology and molecular mechanisms will expand.

Accompanied that, the presences of giant pharma companies, such as Roche/ Genentech, Chugai Pharmaceutical, Genor Biopharma, Johnson & Johnson, Merck, Gilead Sciences, Xencor, Numab Therapeutics others, signifies that the sector of trispecific antibodies will prosper further in the forthcoming years as the involvement of giant stakeholders aid to conduct multiple research studies.

Over and above, pharmaceutical companies as well as biotechnology corporations are progressively engaging in strategic collaborations, investments, in addition to acquisitions to influence corresponding expertise and resources in trispecific antibody development domain. These partnerships accelerate research and development, optimize clinical trial design, and enhance market penetration. For instance, in May 2024, Merck has acquired EyeBio with an investment of US$ 3 Billion in order to advance the sector of trispecific antibody. Furthermore, Gilead Science and Merus collaboration deal to discover novel antibody-based trispecific t-cell engagers in March 2024 is another such example.

For the treatment of cancer disorders, a diverse landscape of trispecific antibody candidates is currently under evaluation to treat solid tumors and hematological cancer diseases. However, in the recent years, scientists have expanded the clinical application of trispecific antibody beyond cancer and can be utilized to treat other indications such as eye disorders, viral infections and other, specifying novel avenue. Given their biological complexity as well as anticipated premium pricing, the segment of trispecific assets could feasibly generate multi billion-dollar peak sales in forthcoming years among successful programs.

Looking further ahead, the commercial global market of trispecific antibody is intensifying at a farfetched pace owing to the market drivers like the rising population, involvement of stakeholders, ongoing pre-clinical and clinical trials, augment in technological advancement in immunotherapies domain, rise in awareness for immuno oncology therapy, together with increase in investments and licensing deals. Presently, the US as well as China have become the front runner up in the segment of trispecific immuno therapy due to the rising research in addition to clinical trials.

1. Trispecific Antibody As Targeted Therapy

2. Trispecific Antibody Current Clinical Development & Future Commercialization Outlook

2.1 Current Market Development Scenario
2.2 Future Market Commercialization Outlook

3. Trispecific Antibody Clinical & Market Development Trend Analysis by Region

3.1 US
3.2 China
3.3 EU
3.4 UK
3.5 Japan
3.6 Australia

4. Trispecific Antibodies Therapeutic Clinical Tends By Indications

4.1 Cancer
- 4.1.1 Breast Cancer
- 4.1.2 Colorectal Cancer
- 4.1.3 Lung Cancer
- 4.1.4 Multiple Myeloma
- 4.1.5 Lymphoma
- 4.1.6 Leukemia
4.2 Viral Infections
4.3 Eye Diseases

5. Global Trispecific Antibodies Clinical Trials Overview

5.1 By Country
5.2 By Phase
5.3 By Company
5.4 By Indication
5.5 By Patient Segment

6. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II

7. Trispecific Antibody Market Dynamics

7.1 Market Drivers
7.2 Market Challenges

8. Recent Trends in Trispecific Antibody Market: Partnerships, Acquisitions, Collaboration, & Investments

9. Combinations Approaches for Bourgeoning Trispecific Antibody

9.1 Immunotherapy
9.2 Radiotherapy

10. Platforms Used For Pioneering Trispecific Antibody

10.1 Tavotek Biotherapeutics - TavoSelect Platform
10.2 Tavotek Biotherapeutics - TavoPrecise Platform
10.3 Purple Biotech - Tribody Antibody Platform
10.4 Simcere Zaiming's - T-Cell Engager Polyspecific Antibody Technology Platform
10.5 Ichnos Sciences - BEAT Platform
10.6 Molecular Partners - DARPin Platform
10.7 Merus - Triclonics Platform

11. Competitive Landscape

11.1 AbbVie
11.2 Antibody Studio
11.3 Beijing Mabworks Biotech
11.4 Biocytogen Pharmaceuticals
11.5 Chimagen Biosciences
11.6 Chiome Bioscience
11.7 Genor Biopharma
11.8 GT Biopharma
11.9 Harpoon Therapeutics
11.10 Ichnos Sciences
11.11 KisoJi Biotechnology
11.12 L and L Biopharma
11.13 Lyvgen Biopharma
11.14 Numab
11.15 OPKO Health
11.16 Sanofi
11.17 Sichuan Baili Pharmaceuticals
11.18 TG ImmunoPharma

List of Figures

Figure 1-1: Trispecific Antibody as Targeted Therapy
Figure 2-1: Strategies to Develop Next Generation Trispecific Antibody
Figure 2-2: Aspects Influencing Future of Trispecific Antibody
Figure 3-1: CB307 Phase I Study (NCT04839991) - Initiation & Completion Year
Figure 3-2: SAIL66 Phase I Study (NCT05735366) - Initiation & Completion Year
Figure 4-1: BR115 Phase I Study (NCT06388902) - Initiation & Completion Year
Figure 4-2: NM32-2668 Phase I Study (NCT06299163) - Initiation & Completion Year
Figure 4-3: Trispecific Antibody Benefit to Treat Colorectal Cancer
Figure 4-4: Chimagen Biosciences Pipeline
Figure 4-5: HPN328 (MK-6070) with Atezolizumab Phase I/II Study (NCT04471727) - Initiation & Completion Year
Figure 4-6: Genor Biopharma Pipeline
Figure 4-7: GB263T Phase I/II Study (NCT05332574) - Initiation & Completion Year
Figure 4-8: SIM0500 Phase I Study (NCT06375044) - Initiation & Completion Year
Figure 4-9: JNJ-79635322 Phase I Study (NCT05652335) - Initiation & Completion Year
Figure 4-10: MBS314 Phase I/II Study (NCT06232096) - Initiation & Completion Year
Figure 4-11: Trispecific Antibodies FDA Designations
Figure 4-12: HPN217 Phase I Study (NCT04184050) - Initiation & Completion Year
Figure 4-13: PIT565 Phase I Study (NCT05397496) - Initiation & Completion Year
Figure 4-14: JNJ-80948543 Phase I Study (NCT05424822) - Initiation & Completion Year
Figure 4-15: 1A46/ BR110 Phase I/II Study (NCT05987605) - Initiation & Completion Year
Figure 4-16: KL-HIV-Tri01 Phase I Study (NCT06117657) - Initiation & Completion Year
Figure 4-17: Restoret (EYE103) - Tetravalent, Tri-Specific Antibody Binding Sites
Figure 4-18: Restoret/ EYE103 Phase I/II Study (NCT05919693) - Initiation & Completion Year
Figure 4-19: Eluminex Ophthalmics Clinical Trispecific Pipeline for Eye Ailments
Figure 5-1: Global - Trispecific Antibodies Clinical Trials by Country, 2024
Figure 5-2: Global - Trispecific Antibodies Clinical Trials by Phase, 2024
Figure 5-3: Global - Trispecific Antibodies Clinical Trials by Company
Figure 5-4: Global - Trispecific Antibodies Clinical Trials by Indication, 2024
Figure 5-5: Global - Trispecific Antibodies Clinical Trials by Patient Segment, 2024

Figure 7-1 : Trispecific Antibody - Market Drivers

Figure 7-2: Key Players in Trispecific Antibody Market
Figure 7-3: Trispecific Antibody - Market Challenges
Figure 9-1: JNJ-87801493 with JNJ-80948543 & JNJ-75348780 Phase I Study (NCT06139406) - Initiation & Completion Year
Figure 9-2: Radiolabelled CB307/ 89Zr-CB307 Phase I Study (NCT05836623) - Initiation & Completion Year
Figure 10-1: Purple Biotech - Tribody Antibody Platform
Figure 10-2: DARPin Platform - Molecular Partners
Figure 10-3: Merus - Triclonics Platform
Figure 11-1: GT Biopharma - Clinical Pipeline

List of Tables

Table 3-1: US -Ongoing Clinical Trials for Trispecific Antibodies (May'2024)
Table 3-2: EU -Ongoing Clinical Trials for Trispecific Antibodies (May'2024)
Table 3-3: Australia -Ongoing Clinical Trials for Trispecific Antibodies (May'2024)

Have a question?